Re the Chinese investor, might be noteworthy that on December 3rd at the ASH Annual Meeting (American Society of Haematology) in California, there was a presentation on "A Phase I Trial of iPSC-Derived MSCs (CYP-001) in Steroid-Resistant Acute GvHD."
https://ash.confex.com/ash/2018/webprogram/Paper110432.html
Notable participants (titles/qualifications excluded to prevent eye strain), were -
Adrian Bloor, David T Yeung, Igor Slukvin, Kilian Kelly, and John E.J. Rasko.
Gene Therapy expert and clinical heamatologist Prof John Rasko heads the University of Sydney's newly established Li Ka-Shing Cell and Gene Therapy Initiative.
Re the Chinese investor, might be noteworthy that on December...
-
- There are more pages in this discussion • 1,780 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $52.99M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 29.5¢ | 27.5¢ | $29.94K | 106.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 10159 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CYP (ASX) Chart |